Impact of reintervention for failing upper-extremity arteriovenous autogenous access for hemodialysis  by Hingorani, Anil et al.
1004
that this trend of increasing numbers of nonmaturing or
failing AVFs may be more frequently encountered in mul-
tiple centers.
Interestingly, the few previously published series that
have examined this issue have mostly focused on revision of
radial-cephalic AVFs (RCAVFs) rather than the upper-arm
AVFs that comprised the majority of AVFs placed at our
institution.3-5 With the increasing average age of the end-
stage renal disease population, it may be expected that the
availability of a distal cephalic vein and radial artery become
more and more limited for AVF placement. Consequently,
additional upper-arm AVFs will need to be placed more
often to maximize the use of veins for access, and the num-
ber of failing upper-arm AVFs may increase. Because the
management of these failing AVFs is poorly addressed in
the literature, we reviewed our recent experience with sal-
vage procedures for AVF in an effort to better guide the
surgeon in these challenging and difficult problems.
MATERIAL AND METHODS
Of the 474 AVFs placed at our institution in 380
patients between June 1997 and March 2001, 75 revision
procedures were performed in 49 AVFs (10%) in 46
patients. There were 18 RCAVFs (37%), 23 brachial-
Although previously published guidelines have sug-
gested that at least 50% of new hemodialysis accesses are
arteriovenous fistulae (AVFs), our work during the past 3
years of implementing an all-autogenous policy demon-
strated that more than 95% of the patients can undergo
this type of protocol.1,2 This is primarily a result of the
combination of aggressive upper arm vein use, liberal use
of venous duplex scanning, and appreciation of the need
to revise nonfunctional AVFs with similar techniques to
that of salvage of failing lower-extremity bypasses. As a
consequence of this all-autogenous policy, we have
encountered an increasing number of nonmaturing and
failing AVFs (Table I). Indeed, if some of these proposed
guidelines do take effect nationwide, it might be expected
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Purpose: Although large published series have described their experience with the management of failed or failing pros-
thetic arteriovenous grafts for hemodialysis, there are scant data regarding failing arteriovenous fistulae (AVFs). To
analyze the management of nonfunctioning or nonmaturing AVFs, we reviewed our experience with salvage procedures
for these AVFs.
Material and Methods: Of the 474 AVFs placed at our institution in 380 patients between June 1997 and March 2001,
75 revisions were performed in 46 patients (49 AVFs). Ages of these patients ranged from 29 to 94 years (mean, 68 ±
1.4 years). Diabetic patients comprised 51%, and hypertensive patients comprised 75%. Twenty patients underwent 26
vein patch angioplasties, and 17 patients underwent 24 balloon angioplasties. Four patients required four vein inter-
positions, and 12 patients underwent 12 revisions of the fistula to a more proximal level. Extended salvage procedures
consisted of four turn-downs to the basilic vein for proximal cephalic vein thrombosis or stenosis and five extension
bypasses to the axillary or jugular vein for subclavian vein thrombosis.
Results: Follow-up ranged from 1 to 31 months (mean, 10 months). The patients who underwent open revisions tended
to need fewer subsequent procedures. However, primary patency of the vein patch angioplasty was not significantly
better as compared with balloon angioplasty (P = .8) by life table analysis. Patency after revision of a radial cephalic
fistula and brachial cephalic fistula were not statistically different. One interposition failed during the follow-up, and
one revision to a more proximal level thrombosed during the follow-up. Two of the turn-down procedures had throm-
bosed at 2 and 11 months. The remaining two turn-down procedures have remained functional at 1 and 24 months.
One of the extensions thrombosed at 8 months whereas the other four have remained functional at 1, 6, and 8 months.
Conclusions: Despite the limited follow-up data, this review suggests that simple and extended salvage procedures may
allow maturation and add to the life span of AVFs for hemodialysis. In addition, these data suggest an advantage for
open techniques as compared with percutaneous techniques but only in terms of requiring fewer subsequent proce-
dures. (J Vasc Surg 2001;34:1004-9.)
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cephalic AVFs (BCAVFs) (47%), and 8 brachial-basilic
AVFs (BBAVFs) (16%) that underwent revision during
this time period. Ages of the patients ranged from 29 to
94 years (mean, 68 ± 1.4 years). Men made up 53% of the
revisions. Diabetic patients comprised 51%, and hyperten-
sive patients comprised 75%. Former or active tobacco use
was noted in 35%. There were no statistical differences
between the revision group and the AVFs performed dur-
ing this period. Ten of these patients had previously
thrombosed prosthetic arteriovenous grafts (AVGs).
Three of these previous AVGs were ipsilateral to the AVF.
The original construction of the AVF was performed
under a standard protocol. With the patient under local
anesthesia with intravenous sedation, regional block, or
general anesthesia, the vein was mobilized. The artery was
exposed through a separate incision or through the same
incision. The vein was passed through a subcutaneous tun-
nel after venodilation, and an end-to-side anastomosis was
created using a 6-mm to 10-mm arteriotomy. The fistula
was allowed to mature for 4 to 6 weeks before cannulation.
Of the entire series of patients, 64 of the AVFs placed
during this period completely thrombosed and the patients
underwent placement of a new AVF. These were included
in the analysis as new AVFs, not as revisions. One AVF was
ligated because of an infected pseudoaneurysm with a large
skin defect and replaced with a new AVF. Five AVFs were
ligated because of steal syndrome with nonreconstructable
distal atherosclerotic disease. One AVF was ligated because
of venous hypertension caused by proximal deep venous
thrombosis that was not amenable to bypass and had failed
thrombolysis. One patient had an elective ligation of an
AVF before a fixation of her humeral fracture after exten-
sive discussion with her orthopedic surgeon.
Unfortunately, routine postoperative duplex scan sur-
veillance was not performed because the patients were not
our own and would not follow-up, especially because the
patients’ primary physicians were not supportive of this
practice. Clinical criteria were used for detection of a non-
maturing (n = 24) or failing AVF. Patients who were noted
to have a poor thrill on physical examination, high venous
pressures, poor flows on hemodialysis, or excessive bleed-
ing after hemodialysis were evaluated for revision of the
AVF. Patients were evaluated with intraoperative percuta-
neous angiography.
AVF with localized distal thrombosis or stenosis
underwent proximal revision if feasible. Thrombosed
AVFs (n = 45) were replaced with new AVFs but did not
undergo thrombectomy or thrombolysis. This is based on
our previous poor experience with thrombectomy or
thrombolysis. Intraoperative angiography was performed
to assess the stenotic lesions. Twelve nonmaturing
RCAVFs were abandoned because of extensive myointimal
hyperplasia of the distal cephalic vein and were replaced
with new AVFs. Stenotic lesions in the vein (<70%) under-
went balloon angioplasty for lesions >1 cm long and open
vein patch angioplasty for lesions <1 cm. Vein interposi-
tion was used if >4 cm of the vein was stenotic. Vein for
reconstructions was harvested from the distal greater
saphenous vein, external jugular, and tributaries of the dis-
tal cephalic vein. There were no harvest-site wound com-
plications. Synthetic patch angioplasty (Vascultek, Sulzer
Medica, Zurich, Switzerland,) was performed if no venous
tissue was available without compromising future venous
reconstructions (n = 2). Revision of the localized distal
anastomosis to a more proximal location was performed
for stenosis or occlusion of the distal portion of an AVF.
The AVF was transected in the distal to the stenotic area
and reanastomosed to the proximal artery. Stenotic lesions
of the subclavian vein underwent balloon angioplasty with
stent placement. Failed balloon angioplasties underwent
open surgical revision when accessible.
Follow-up. Patients were followed with duplex ultra-
sound scanning selectively and physical examinations.
Hospital, office, and dialysis center charts and the Social
Security Death Index were reviewed. Data collection was
done via chart review, personal and telephone interviews,
and review of the dialysis records. Patency was defined as
functional patency with adequate dialysis.
Fig 1 Patency of patch angioplasty versus balloon angioplasty
(not including subclavian vein).
Fig 2 Comparison of RCAVFs, BCAVFs, and BBAVFs.
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Statistical analysis. Data were compared using χ2 test
and Student t test (Winks 4.21, Texasoft, Cedar Hill, Tex,
and Graphpad, Instat, San Diego, Calif). Fistula patency
rates were determined by the life table method of analysis
using the statistical formulae recommended by the Ad Hoc
Committee on Reporting Standards, Society for Vascular
Surgery/North American Chapter, International Society
for Cardiovascular Surgery.6 Log-rank comparison for sta-
tistically significant differences (P < .05) between life table
groups was performed with SPSS (version 9.0, SPSS
Science, Inc, Chicago, Ill). Log-rank test was performed in
conjunction with Kaplan-Meier survival analysis.
RESULTS
For the 474 AVFs placed during this period, follow-up
ranged from 0 to 42 months (mean, 12.9 ± 0.53 months).
During this time period, six patients were found to have
normal fistulograms despite excessive bleeding from the
cannulation sites. The primary patencies of the RCAVF,
BCAVF, and BBAVF at 12 months were 75%, 86%, and
89%, respectively. Of the 49 AVFs that underwent revi-
sions, follow-up ranged from 1 to 31 months (mean ±
SEM, 10 ± 1.2 months). One patient was lost to follow-
up. Of these AVFs, 47 were found to have stenoses, and
two were found to have a localized thrombosis. Of the
stenotic AVFs, 24 presented with a failure to mature.
Twenty patients have undergone 26 vein patch angioplas-
ties, and 17 patients have undergone 24 balloon angio-
plasties. Balloon angioplasty of subclavian vein was
performed in six cases in four patients. These were rou-
tinely stented. Four patients underwent four interposi-
tions, and 12 patients underwent 12 revisions of the fistula
to a more proximal level. Extended salvage procedures
consisted of four turn-downs to the basilic vein for proxi-
mal cephalic vein thrombosis or long segmental stenosis in
four patients and five extension bypasses to the axillary or
jugular vein for subclavian vein thrombosis in five patients.
Sixteen patients had to undergo two or more revisions, of
whom three had eventual thrombosis of the AVF. Seven
AVFs after revision had eventual thrombosis of the AVF.
Of the 24 patients who presented with nonmaturing
AVFs, 13 (54%) had to undergo more than one procedure
to obtain adequate arteriovenous access as compared with
the 10 of the 22 patients (45%) who presented with failing
AVF and had to undergo more than one procedure to
obtain adequate arteriovenous access.
Primary patencies of the vein patch angioplasty or all of
the open procedures were not significantly different by
multiple life table analyses as compared with balloon
angioplasty, whether or not subclavian vein angioplasties
were included (P > .5) (Fig 1) (SEM > 10% at 15 months).
Primary patency after revision of an RCAVF and a BCAVF
was not statistically different (Fig 2). One interposition
failed during the follow-up, and one revision to a more
proximal level thrombosed at 10 months. Two of the turn-
down procedures had thrombosed at 2 and 11 months.
The remaining two have remained functional at 1 and 24
months. One of the extensions thrombosed at 8 months,
whereas the other four have remained functional at 1, 6,
and 8 months. One patient required evacuation of a
hematoma after revision of an AVF. Table II lists the inter-
val between placement of the AVF and the initial revision.
Fifteen of the 24 balloon angioplasties (62%) of out-
flow vein underwent further procedures whereas 19 of the
51 open procedures underwent subsequent procedures
(37%) (P = .036). However, when examined by the num-
ber of accesses, 8 of the 17 (47%) AVFs that underwent
balloon angioplasty underwent a subsequent procedure,
whereas 13 of the 46 AVFs (28%) that underwent open
procedures underwent subsequent procedures (P = .11).
Sixteen of the balloon angioplasties were of the AVF itself,
1 of the brachial vein, 6 of the subclavian vein, and 1 of
the axillary vein. One patient underwent balloon angio-
plasty and stent of the subclavian artery twice. One patient
had failed repeat balloon angioplasty and upon explo-
ration was found to have rupture of the vein graft. This
was repaired with an interposition vein graft with subse-
quent use of the AVF for hemodialysis.
Three patients continue to use a tunneled cuffed
catheter because of recent surgery. One additional patient
is still using a tunneled catheter because of refusal to
Table II. Interval between placement and initial revision
of AVF
RCAVF BCAVF BBAVF
Months ± SEM 7 ± 2 5 ± 1 7 ± 2.6
Data presented as mean that was equivalent to the median (P = .6).
Table I. Annual numbers of AVFs placed and revised
AVFs placed AVFs revised
Year Total RCAVF BCAVF BBAVF Total RCAVF BCAVF BBAVF
1997 3 2 1 0 0 0 0 0
1998 87 33 33 21 10 0 9 1
1999 101 45 43 13 15 7 4 4
2000 229 108 94 36 36 17 14 5
2001 (up to March) 54 18 20 16 14 5 5 4
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undergo AVF revision. Two patients were converted to
AVGs after multiple AVF revisions, and one patient was
converted to AVG at an outside institution. One patient
with a functional fistula received a transplant after 1 year
of using the AVF, and one patient no longer needed dial-
ysis after 6 months of using the AVF. Ten patients died
during the follow-up period.
DISCUSSION
The projection based on recent national data is that
the number of patients with end-stage renal disease in the
United States will rise to 520,000 persons by 2010 and
that the cost of maintaining the Medicaid end-stage renal
disease program will balloon to $28 billion.7 As the cost of
maintaining the dialysis access skyrockets, the issues of
cost control and quality of care have become significant.
In an effort to address some of these issues, the Dialysis
Outcome Quality Initiative guidelines were published in
1997.8 Central to the algorithm proposed by the guide-
lines was the placement of AVFs to decrease the number
of repeated procedures necessary to maintain the patency
of prosthetic hemodialysis access. The question of whether
this increased focus on AVF placement has resulted in
improved vein use nationwide for the estimated total of
259,000 end-stage renal disease patients in the United
States as of December 1999 remains unclear. Data from
1999 suggest that 27% of accesses being used for
hemodialysis were AVFs with no improvement from the
1997 data.9 Indeed, earlier US studies demonstrated a
decrease in the percentage of patients with AVFs being
placed for access during the 1980s with little change since
then.10 Whether some of this reluctance to change exist-
ing practices may be a result of controversy over the supe-
riority of AVF as compared with AVG or a result of a
differential in the fee schedules for AVFs as compared with
AVGs remains an open issue.
In contrast, investigators from Europe and Canada
have demonstrated much higher vein use rates.11 Despite
this, few data on revisions of AVF to maintain an access
have been written in the world literature.12,13 Among the
largest series is a report from Japan in which 287 RCAVFs
were placed between 1985 and 1994.14 A total of 157
patients underwent operative revision during a mean fol-
low-up of 6 years. Of these, 115 were revised to a more
proximal site. Their data reported that 0.8 revisions were
needed during the lifetime of a functional AVF. These
authors suggested that patients who have undergone revi-
sion of their AVF tended to require subsequent revisions.
They further proposed that the secondary patency rate in
diabetic patients was nearly identical to that of patients
who had not undergone a revision procedure. Therefore,
they concluded that revision of these AVFs is a reliable pro-
cedure and achieves an acceptable patency rate. However,
because the recommended standards for reporting patency
were not used, these data contain serious flaws.
In another series of 63 patients with nonfunctional
AVFs, 56 of the AVFs were RCAVFs. The access could be
salvaged in 82% by a combination of balloon angioplasty
(n = 21) and ligation of tributaries (n = 52), and 75% were
functionally patent at 1 year. These excellent results are
intriguing in that the use of ligation of tributaries seems to
be unparalleled as compared with any other series. In
other reported series, most of the nonmaturing AVFs
seem to have been caused by stenosis rather than excessive
tributaries.3,17 Whether some of these AVFs may have
eventually matured with these tributaries intact remains an
open question.5
Nonetheless, it is clear from these papers and our data
that maintaining this type of all-autogenous policy
requires that the surgeon be aggressive and creative and
have a variety of techniques in his repertoire to salvage the
fistulae. We have found that a combination of techniques,
such as extension bypass to contralateral axillary vein,
jump to the external or internal jugular vein, transposition
of the jugular vein, and balloon angioplasty and stent of
the subclavian and innominate veins, are necessary tools in
the armamentarium of the surgeon to maintain these
accesses.16-18 These are in addition to the simple proce-
dures of patch angioplasty and interposition. A combina-
tion of these techniques can allow up to 10% of these AVFs
to mature or to continue to be used for hemodialysis
access. Furthermore, because this group of patients who
require these more complex additional procedures is often
quite debilitated because of underlying medical condi-
tions, the importance of technical expertise needs to be
highlighted.
Although follow-up is limited in this set of data, the
results suggest that simple and extended salvage proce-
dures may allow maturation and add to the life span of
AVF for hemodialysis. What type of salvage procedure
would be the most beneficial remains an issue for further
examination. Although there are no randomized prospec-
tive data for salvage of AVF between open surgical and
endovascular techniques, there is a randomized trial of 80
failed AVGs.19 These authors found higher costs for the
endovascular-treated arm but equivalently poor patencies
in each arm. Whether these data can be applied to AVF is
not resolved because previous literature examining the use
of balloon angioplasty for AVF has not mentioned long-
term patency or suggested limited primary patency in a
small number of patients.3,4 However, these data also pro-
posed that much better results would be obtained with
repeated procedures to maintain patency.
In our nonrandomized series, only stenosis <1 cm or a
lesion in the subclavian vein would have undergone bal-
loon angioplasty. Longer lesions would routinely undergo
vein patch angioplasty, interposition, or a revision of the
AVF. In spite of this, our data suggest an advantage for
patch angioplasty as compared with percutaneous tech-
niques, but only in the total number of subsequent proce-
dures needed. These limited results have led us to limit the
use of balloon angioplasty to intrathoracic lesions. These
data suggest that further investigation is clearly indicated
to delineate the role of each modality in the failing or non-
maturing AVF. On the other hand, because the number of
BBAVFs that underwent revision is so small, very few data
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can be gleaned from these patency data other than that revi-
sions of RCAVFs seem to fare as well as revision of BCAVFs.
Despite this aggressive all-autogenous policy, it was
noted that three patients could not be established on
hemodialysis via AVF because of repeated thrombosis and
stensoses. These patients had normal-appearing veins as
assessed by clinical examination, duplex scan, or angiogra-
phy. None of these patients has a known hypercoagulable
syndrome. Comparison of these patients’ characteristics
and the remainder did not reveal which subset of patients
should undergo placement of AVG rather than AVF. Based
on our experience, we feel that there may indeed be a very
limited subset of patients in whom AVF placement may not
be possible or recommended especially if the expected life
expectancy is <2 months. However, the subset of patients
requiring fewer revisions if an AVG were placed rather than
an AVF has not been defined. Therefore, we continue to
advocate that AVG placement should only be performed
after all autogenous options have been exhausted.
These data suggest that embarking on an all-autoge-
nous access policy entails maintaining these accesses with
a variety of techniques. Although these data are prelimi-
nary, they suggest that the procedures for salvage of non-
maturing AVFs and failing AVFs may be worthwhile. As
more centers accumulate further data, many of the unan-
swered questions that have been raised by our experience
will no doubt be further explored.
We thank Anne Ober for technical assistance.
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Dr Michael B. Silva, Jr (Lubbock, Tex). Drs Ascher,
Hingorani, and their colleagues at Maimonides Medical Center in
Brooklyn occupy a prominent position in the advanced guard of
the national movement to increase use of autogenous fistulas for
hemodialysis access. They have successfully confirmed the impor-
tance of noninvasive and upper extremity duplex exams and the
attendant use of vein transposition to arrive at a near all-autolo-
gous practice over the past 4 years. They now offer us insight into
the next logical area of investigation for such a practice, their
experience in treating the failing and failed fistula.
I have the following questions for the authors, the answers to
which may help clarify their message.
1. What is your approach to the recently thrombosed AV fis-
tula? How do you define the extent of thrombus and do
you not advocate an attempt at lytic or surgical salvage? I
noted that no patient within this series received throm-
bolytic therapy.
2. You note more favorable results with open patch angioplasty
as compared to percutaneous balloon angioplasty. You report
both vein patch and prosthetic patch angioplasty experience.
Is your experience sufficient to discern a difference of success
rates of the two types of material?
3. You have a very high percentage of diabetics within the revi-
sion group. How does this compare to your overall access
population? Have you identified any characteristics within
your access population which might predispose them to
problems with their fistulas?
4. And finally, you correctly define a successful fistula as one
which supports dialysis, eschewing simple patency as an end-
point. Have you analyzed your 4-year data to be able to
DISCUSSION
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report your primary assisted patency, which would be inter-
ventions on problem grafts still supporting dialysis, versus
secondary patency, interventions, and salvage of those grafts
not supporting dialysis?
This manuscript deals with an important and timely topic of
interest to all vascular surgeons working not only to meet targets
established by the DOQI Committee, but struggling to achieve
good and lasting results in this challenging population.
I’d like to thank the authors for providing this manuscript for
advance review and the Society for the privilege of the floor.
Dr Anil Hingorani. Thank you for those comments.
In our set of patients, no, we did not actually do thrombec-
tomies of AV fistula or use lytic therapy. However, having said
that, there are some patients who had a large fistula that was well
matured; and if there was a small segment that was thrombosed,
a distal radial-cephalic or a proximal portion of localized throm-
bosis of a fistula such as a brachiocephalic, sometimes we would
do surgical revisions either higher up the radial artery or excising
the thrombosed portion.
I do think that there is some literature supporting using this.
However, having said that, the results have not been that great.
The numbers of studies that have looked at salvaging thrombosed
AV fistulas are not large. Probably the largest one that I can think
of is by Brethed, who has written extensively on AV access proce-
dures, and his results long term were not that encouraging.
We only used two prosthetic patches, in patients who had
no other alternatives, without compromising other possible fis-
tula sites. And we weren’t able to use the lower-extremity
greater saphenous veins, and so we really can’t say that much
about comparison with vein patching angioplasties. Both of
those restenosed.
When we looked at the percentage of diabetics, that’s true,
the percentage of diabetics in this population is approximately
double that of our 380 patients taken over the last 4 years, and
that was found to be statistically significant.
Some of the other characteristics of these patients, approxi-
mately 10 of these patients had prior AV grafts, three of which
were on the ipsilateral side, which was again higher than our over-
all AV fistula patients.
Looking at our primary assisted patency rates over the last 4
years, we have not looked at the fistulas that are patent but not
supporting dialysis as of yet, but I think those are two very impor-
tant questions. Part of these patients that we presented today
were not only failing but nonmaturing fistulas. We lumped them
together. But looking at just the ones that have not been able to
support dialysis may actually be a separate population, even
though they may be due to stenosis or occlusions. But that may
be actually a separate issue to look at.
Dr John J. Ricotta (Stony Brook, NY). Anil, that was very
nice. I have a couple of questions.
How many of these patients are presenting for their first
access? I always thought that the people in Brooklyn were worse
than the people on Long Island, but maybe that’s not so. It seems
like we have a lot harder time, even though we’re going toward
an all-autogenous policy, our revision rate—I haven’t looked at it
specifically—but my sense is that it’s higher than that. So I’m just
curious whether these are people that you’re seeing for first access
or people that have had multiple accesses and you’re now picking
them up for revision.
The second question I’d like you to clarify is, when you do a
radiocephalic fistula how often are you at the wrist and how often
are you higher up? Because I think very often that the most dis-
tal vein is not terribly good.
My third question is how many of these problems have been
within the vein segment, in other words, not at the top or not at
the bottom but in the vein segment?
Dr Hingorani. Most of these patients were primary accesses;
greater than 90% were their first time around. We actually looked
at some of these issues. And as I said, only 10 of these patients
had prior AV grafts.
When we looked at the radiocephalic, yes, preferentially we
will go for the wrist. However, you really need to assess it intra-
operatively. Very often we will go up a centimeter or two higher
and we do routinely use duplex imaging to try to assess that area
since the nurses keep going after it.
A fair number of the stenoses were actually in the interven-
ing segment, not high up, not all the way down by the wrist,
probably around 30% to 40% of them.
Dr David Fox (New York, NY). At St Luke’s Roosevelt we
also adopted Mike Silva’s philosophies about 3 years ago and
adopted an all-autologous policy. Our autologous fistula creation
rate is around 90%. And our experience mirrors yours to a large
degree. We have seen a significant number of revisions. We’ve in
general chosen angioplasty as the means of treating that. And I
can’t give you numbers at this time, but it seems to be a useful
technique.
We have not hesitated to declot fistulas using interventional
means. And while it doesn’t always work, oftentimes we uncover
a single lesion which is amenable to angioplasty. So I would
encourage its use.
Overall, it has been a little bit disappointing in that we are
having to intervene more often than we thought we would have
to initially. And I wonder a little bit, although I’m still enthusias-
tic about the all-autologous approach, whether it does challenge
one of the basic goals of DOQI in that they were trying to have
a decreased intervention rate and therefore decreased cost. I’m
just wondering about your thoughts about that.
Dr Hingorani. I actually agree with you. I think there are
some patients in whom this doesn’t work. They don’t have the
veins. I know of three patients who had multiple fistulas, multiple
AV grafts, and it just didn’t work. We really never got them off
the Tesio catheters.
The characteristics of those patients are difficult to assess
based on three patients. I don’t know if some of them just had
bad veins. Because angiographically they looked fine. By duplex
they looked fine. And on clinical exam, when you looked at the
vein, it looked normal. I don’t know if they were dropping their
blood pressure and they just kept thrombosing. Some of them
were already on Coumadin. So I don’t have that answer.
Right now the official party line is that you’ve got to get rid of
the catheters, according to DOQI, as soon as possible. However, I
think there is still a place for these catheters if the patients have a
life expectancy less than 2 months, I don’t see the purpose of
putting in a fistula. This is one point that  DOQI does not address.
